Trial Condition(s):
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the treatment of Gram-Negative Pneumonia (INHALE 1)
Bayer Identifier:
13084
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Trial Purpose
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and more effective than placebo (aerosolized normal saline) administered as an aerosol by the PDDS Clinical every 12 hours, in intubated and mechanically-ventilated patients with Gram-negative Pneumonia. The secondary endpoint objectives are to evaluate the superiority of aerosolized BAY 41-6551 versus aerosolized placebo in pneumonia-related mortality, the Early Clinical Response at Day 10, the days on ventilation, and the days in the intensive care unit (ICU).
Inclusion Criteria
- Males and non-pregnant, non-lactating females, 18 years of age or older - Intubated and mechanically-ventilated - Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on chest radiograph - Presence of Gram-negative organism(s) by either Gram stain or culture of respiratory secretions, or suspected Gram-negative pathogen - Impaired oxygenation - Clinical Pulmonary Infection Score (CPIS) of at least 6 - Presence of a multi-drug resistant (MDR) organism in a pre-therapy respiratory specimen OR at least two risk factors for MDR organisms
Exclusion Criteria
- History of hypersensitivity to amikacin or other aminoglycosides - Has received antibiotic therapy for Gram-negative pneumonia for greater than 48 hours at the time of randomization - Known or suspected bacteremia secondary to Staphylococcus aureus - A positive urine and/or serum beta-human Chorionic Gonadotropin pregnancy test - Patients with a serum creatinine > 2 mg/dL (177 µmol/L) [Exception: Patients with a serum creatinine > 2 mg/dL (177 µmol/L) and being treated with continuous renal replacement therapy (Continuous Veno-Venous Hemodialysis and CVVHemoDiafiltration) or daily hemodialysis will receive the aerosol study drug treatment] - Has been on mechanical ventilation for > 28 days - Is participating in or has participated in other investigational interventional studies within the last 28 days prior to study treatment - The risk of rapidly fatal illness and death within 72 hrs, or any concomitant condition not related to ventilator-associated pneumonia that, in the opinion of the investigator, precludes completion of study evaluations and the course of therapy - Has an Acute Physiology and Chronic Health Evaluation (APACHE) II score < 10 - Patients receiving veno-venous extracorporeal circulation membrane oxygenation (V-V ECMO)
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Mineola, United States, 10065 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Miami, United States, 33125 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hazard, United States, 41701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Phoenix, United States, 85008-4956 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Birmingham, United States, 35233 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cincinnati, United States, 45267-0769 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site New York, United States, 10065 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cleveland, United States, 44195 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Greensboro, United States, 27401 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site New York, United States, 10019 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site São José do Rio Preto, Brazil | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Belo Horizonte, Brazil, 30150 221 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Toronto, Canada, M5T 2S8 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Barranquilla, Colombia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cali, Colombia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Campinas, Brazil, 13060904 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Brooklyn, United States, 11215 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Taipei, Taiwan, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Oklahoma City, United States, 73117 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Columbus, United States, 43215 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Mobile, United States, 36617 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Muncie, United States, 47303 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Charleston, United States, 29425 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Danbury, United States, 06810 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Las Vegas, United States, 89109 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hartford, United States, 06102 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Springfield, United States, 65803 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Taipei, Taiwan, China, 11217 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tainan, Taiwan, China, 710 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Monterrey, Mexico, 64460 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Aguascalientes, Mexico, 20000 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site San Luis Potosí, Mexico, 78240 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Guadalajara, Mexico, 44340 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site México, D.F., Mexico, 07760 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Blacktown, Australia, 2148 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Clayton, Australia, 3168 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 137-701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 136-705 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Seoul, South Korea, 138-736 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wollongong, Australia, 2500 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kaohsiung, Taiwan, China, 82445 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ankara, Turkey, 06100 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Trabzon, Turkey, 61080 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Chiang Mai, Thailand, 50200 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Khon Kaen, Thailand, 40002 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Newark, United States, 19713 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Atlanta, United States, 30342 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Youngstown, United States, 44501 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Zlin, Czech Republic, 762 75 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Praha 10, Czech Republic, 100 34 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Barranquilla, Colombia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kalamazoo, United States, 49007 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Quezon City, Philippines, NCR 1100 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Quezon City, Philippines, 1105 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Hollywood, United States, 33021-5421 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Butte, United States, 59701 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Cleveland, United States, 44109-1998 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Ottawa, Canada, K1H 8L6 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kingston, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Iowa City, United States, 52242 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Asheville, United States, 28801 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tampa, United States, 33606-3508 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Springfield, United States, 62702 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Quebec, Canada, G1V 4G5 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site St. Louis, United States, 63110-1093 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Montreal, Canada, H1T 2M4 | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative Pneumonia
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
2
Primary Outcome
- Number of Participants Surviving Through LFU VisitThe primary efficacy variable is Survival through the late follow-up (LFU) visit. Survival is achieved when the participant is alive through the LFU visit. No other factors are considered in the evaluation of survival.Timeframe: Up to 28-32 days after start of study treatment
Secondary Outcome
- Number of Participants with Adjudicated Pneumonia-Related Death Through LFU VisitDeath through LFU visit was adjudicated as pneumonia-related or pneumonia-unrelated for participants in the amikacin inhale group and participants in the placebo group.Timeframe: Up to 28-32 days after start of study treatment
- Number of Participants with Early Clinical ResponseEarly Clinical Response was determined by the following: 1. CPIS scoring at Days 3, 5, and 10 compared to baseline (a. On Day 3, CPIS increase from baseline by at least 2 points was considered a failure. b. On Day 5, CPIS decrease from baseline of at least 1 point was not a failure. CPIS of no change from baseline was considered a failure. Any CPIS increase from baseline was a failure. c. On Day 10, CPIS decrease from baseline of at least 2 points was not a failure. CPIS decrease of only 1 point is a failure. Clinical Pulmonary Infection Score of no change was considered a failure. Any CPIS increase from baseline was a failure). 2. All-cause mortality through EOT visit was a failure. 3. The development of empyema or lung abscess through the EOT visit was a failure.Timeframe: Up to 10 days after start of study treatment
- Number of Days on Mechanical Ventilation Through LFU VisitNumber of days on mechanical ventilator was summarized by descriptive statistics. Duration was defined as the number of days from the date of first study drug through the LFU visit. For participants who lived through the LFU visit, the ventilation days were actual days on ventilation with a maximum value of 28 days. For participants who died after Day 28 but on or before their LFU visit, the days on ventilator was censored at 28 days. For participants who died or discontinued off ventilation, the number of days on ventilation was actual days on ventilation with a maximum value of 28 days. For participants who died or discontinued on ventilation, the number of days on ventilation was 28 days. Further analysis of the number of days on mechanical ventilator was to be performed with censoring at Day 28 for subset of participants on ventilation without censoring.Timeframe: Up to 28-32 days after start of study treatment
- Number of Days in the ICU Through LFU VisitNumber of days in ICU was summarized by descriptive statistics. Duration was defined as the number of days from the date of first study drug through the LFU visit. For participants who lived in ICU through the LFU visit, the ICU days were actual days in ICU with a maximum value of 28 days. For participants who died after Day 28 but on or before their LFU visit, the days in ICU was censored at 28 days. For participants who died or discontinued in ICU, the number of days in ICU was 28 days. Further analysis of the number of days in ICU was to be performed with censoring at Day 28 for subset of participants on ventilation and without censoring.Timeframe: Up to 28-32 days after start of study treatment
Additional Information
Copyright © Bayer
Powered by
